Quote:
Originally Posted by Matt
The 33% reduction is for the CRABS, approximately. Tysabri is a lot more effective. The problem with actual numbers is that some people naturally have a much higher relapse rate than others. Presumably someone who has a higher natural relapse rate is more likely to have one or more fewer relapses over the next year or two than someone with a lower natural relapse rate. That's why the relative risk reduction makes more sense to me.
|
But that is also why subjects are randomly assigned to the different conditions (e.g. Ty versus placebo vs. abcr), because the random fluctuation in the usual number of relapses should even out over groups: that is, if the number of subjects in each group is high enough to combat these individual differences.